Table 2.
Univariate and multivariable analysis for biochemical recurrence-free survival in patients with high-risk prostate cancer who underwent radical prostatectomy with and without neoadjuvant treatment
| Variables | Univariate | Multivariable | ||||
|---|---|---|---|---|---|---|
| HR | 95%CI | P value | HR | 95%CI | P value | |
| Age | 0.92 | 0.85–1.00 | 0.035 | |||
| Completion of NAC (medify vs complete) | 0.84 | 0.35–2.02 | 0.689 | |||
| Baseline PSA level (continuous) | 1.02 | 1.01–1.04 | 0.006 | 1.03 | 1.01–1.05 | 0.010 |
| Gleason score at diagnosis (≥8 vs ≤7) | 2.00 | 0.74–5.38 | 0.169 | |||
| Extended lymph node dissection (yes vs no) | 1.51 | 0.60–3.81 | 0.382 | |||
| pT (≥3 vs ≤2) | 4.40 | 1.91–10.13 | < 0.001 | 1.13 | 0.30–4.22 | 0.854 |
| pN (+ or 0) | 4.60 | 1.90–11.11 | 0.001 | 3.94 | 1.06–14.62 | 0.040 |
| Resective margin (positive or negative) | 2.00 | 0.46–8.67 | 0.355 | |||
| Nuclear expression of AR in epitherial cell (High vs low) | 3.00 | 1.22–7.35 | 0.017 | 0.98 | 0.32–3.02 | 0.971 |
| Nuclear expression of GR in epitherial cell (High vs low) | 1.82 | 0.79–4.18 | 0.161 | |||
| Nuclear expression of ERα in stromal cell (High vs low) | 2.37 | 0.84–6.64 | 0.101 | |||
| Nuclear expression of PR in stromal cell (High vs low) | 0.45 | 0.20–1.02 | 0.054 | |||
| Nuclear expression of YAP in epitherial cell (High vs low) | 2.44 | 1.08–5.55 | 0.033 | 3.32 | 1.32–8.37 | 0.011 |
| Cytoplasmic expression of MOB4A in epitherial cell (High vs low) | 1.73 | 0.77–3.91 | 0.190 | |||
NAC neoadjuvant treatment, PSA prostate specific antigen, AR androgen receptor, GR glucocorticoid receptor, ER estrogen receptor, PR progesterone receptor